Peyronie's Disease: Causes, Diagnosis, and Treatment Options

What Is Peyronie's Disease?

Peyronie's disease is a fibrotic condition of the penis in which abnormal healing after micro-trauma deposits rigid collagen plaques within the tunica albuginea, the fibrous sheath that surrounds the erectile tissue. Those plaques create inelastic zones that prevent uniform expansion during erection, producing curvature, indentation, hourglass deformity, pain, and measurable penile shortening. The condition affects sexual function on multiple fronts: mechanical distortion can make penetrative sex difficult or impossible, while pain and body-image distress frequently suppress libido and contribute to psychological erectile dysfunction.

Population-level prevalence data vary because many men never seek care. A cross-sectional study published in the Journal of Sexual Medicine found a self-reported prevalence of 0.5% among 11,420 men, yet community-based ultrasound screening studies place the figure closer to 8.9%, 13% [1][2]. The American Urological Association (AUA) guideline authors concluded that true prevalence is almost certainly higher than clinic-based numbers suggest, owing to patient embarrassment and clinician under-asking [3].

The condition is named for François Gigot de la Peyronie, the French surgeon who described it in 1743, but the underlying pathophysiology was not characterized at a tissue level until collagen typing studies in the late 1980s confirmed that Peyronie's plaques contain predominantly type III collagen with abnormal cross-linking [4].

What Causes Peyronie's Disease?

The leading mechanistic model is a wound-healing disorder triggered by repetitive micro-trauma during sexual activity, though a single acute injury can also initiate the cascade. Normal repair clears fibrin and inflammatory byproducts within weeks. In Peyronie's disease, transforming growth factor-beta 1 (TGF-beta 1) signaling drives myofibroblast activation that overproduces type I and type III collagen, which organizes into a rigid, inelastic plaque rather than normal elastic tissue [5].

Genetic predisposition plays a meaningful role. Between 10% and 20% of affected men also have Dupuytren's contracture of the hand, plantar fibromatosis (Ledderhose disease), or tympanosclerosis, all conditions sharing abnormal fibroblast activity [3]. First-degree relatives of Peyronie's patients carry roughly a threefold elevated risk compared to the general population.

Recognized risk factors include:

• Prior penile trauma (buckling injury during intercourse is the most common precipitant)
• Age over 40, because tunica albuginea elasticity declines with age
• Diabetes mellitus, which impairs vascular supply and alters collagen metabolism
• Hypertension and dyslipidemia, through shared endothelial dysfunction pathways
• Certain medications: beta-blockers and some anti-epileptic drugs appear in case series, though causality is not firmly established
• Perineal or pelvic surgery, including radical prostatectomy, after which up to 16% of men develop new-onset penile curvature [6]

How Peyronie's Disease Is Diagnosed

Diagnosis is clinical. A urologist or sexual medicine specialist takes a detailed history covering symptom onset, curvature direction and degree, pain, change in penile length, and sexual function impact. Objective curvature is measured from a patient-submitted photograph taken during a pharmacologically induced erection (intracavernosal alprostadil or trimix injection in the office) or from a standardized home photograph protocol [3].

Penile duplex Doppler ultrasound adds two pieces of information that change management. First, it locates and quantifies plaque size and calcification, which predicts response to collagenase injection (calcified plaques respond poorly). Second, it assesses penile hemodynamics: peak systolic velocity <25 cm/s or end-diastolic velocity >5 cm/s after intracavernosal injection signals vascular erectile dysfunction that may need concurrent treatment [7].

The AUA guideline recommends validated questionnaires at baseline: the Erection Hardness Score (EHS), the International Index of Erectile Function (IIEF-5), and the Peyronie's Disease Questionnaire (PDQ) [3]. These tools track both functional and psychological impact across the treatment course.

Biopsy is not required for diagnosis and is discouraged because trauma to plaque tissue may worsen fibrosis.

The Acute vs. Stable Phase: Why Timing Changes Treatment

Peyronie's disease follows a biphasic course. Understanding which phase a patient is in determines which treatments are safe to start.

Acute phase (typically 6 to 18 months from symptom onset): The plaque is actively forming. Pain during erection is present in most men at this stage. Curvature may change from week to week. Starting surgical correction during the acute phase risks worsening deformity as the disease continues to evolve. The AUA guideline advises clinicians to defer surgery until the patient has had stable curvature and no pain for at least 3 months [3].

Stable phase: Pain resolves in over 90% of men. Curvature and plaque size are fixed. This is the window for definitive correction, whether by collagenase injection series, plication, or prosthesis implantation.

Spontaneous improvement (defined as >10% reduction in curvature without treatment) occurs in approximately 13% of men during the acute phase and is rare in the stable phase [8]. Watchful waiting alone is therefore not a long-term strategy for men with functional impairment, though short-term observation during the acute phase is reasonable while planning treatment.

Non-Surgical Treatments for Peyronie's Disease

Collagenase Clostridium Histolyticum (Xiaflex)

Collagenase clostridium histolyticum (CCH, brand name Xiaflex) is the only FDA-approved pharmacological treatment for Peyronie's disease. The FDA granted approval in December 2013, based on two key phase III trials: IMPRESS I and IMPRESS II (combined N=832) [9].

In IMPRESS I and II, men with stable Peyronie's disease and curvature between 30 and 90 degrees received up to four treatment cycles (two CCH injections per cycle, 24 to 72 hours apart, followed by penile modeling). At 52 weeks, the CCH group achieved a mean curvature reduction of 17.0 degrees (34% improvement) versus 9.3 degrees (18.2% improvement) in the placebo group (P<0.0001). PDQ bother scores also improved significantly with CCH compared to placebo [9].

The standard protocol is up to eight injections total (four cycles of two injections), with modeling exercises between injections. Contraindications include penile plaques involving the urethra and prior penile surgery at the injection site. The most clinically significant adverse event is corporal rupture, which occurred in 0.9% of CCH-treated subjects in IMPRESS I and II and requires surgical repair [9].

CCH works best for non-calcified plaques with curvature between 30 and 90 degrees. Ultrasound confirmation of absent calcification before injection is standard at most centers offering this treatment.

Penile Traction Therapy

Penile traction therapy (PTT) devices apply sustained mechanical force to promote remodeling of plaque collagen. A 24-week open-label trial (N=55) published in the Journal of Sexual Medicine found mean curvature reduction of 20.4 degrees and mean length gain of 1.3 cm with daily traction use of at least 3 hours [10]. PTT is often combined with CCH during the acute phase and is endorsed by the AUA as an option, though evidence quality remains low compared to CCH injection data.

Oral Agents: What the Evidence Shows

Multiple oral agents have been studied, including pentoxifylline, potassium para-aminobenzoate (Potaba), and phosphodiesterase-5 inhibitors (PDE5i). The AUA guideline concluded that evidence is insufficient to recommend any oral therapy specifically for plaque reduction or curvature correction [3]. PDE5 inhibitors such as tadalafil 5 mg daily may reduce pain in the acute phase and treat concurrent vascular erectile dysfunction, but their effect on curvature itself is not established.

Verapamil intralesional injection was widely used before CCH became available. A Cochrane-reviewed meta-analysis found inconsistent results across trials and no convincing curvature benefit compared to placebo injection [11].

Shock Wave Therapy

Low-intensity extracorporeal shock wave therapy (Li-ESWT) reduces pain in acute-phase Peyronie's disease. Three randomized controlled trials support analgesia. None demonstrated statistically significant curvature reduction versus sham, and the AUA guideline does not recommend shock wave therapy for changing plaque morphology [3]. It remains an option for pain control only.

Surgical Treatment for Peyronie's Disease

Surgery is reserved for men in the stable phase who have curvature impairing sexual function and have either completed a course of non-surgical treatment or elected to proceed directly to surgery. Three surgical approaches are available.

Penile plication (Nesbit procedure and modifications): Sutures shorten the convex side of the penis opposite the plaque to straighten the shaft. Suitable for men with adequate penile length, curvature under 60, 70 degrees, and good erectile function. Penile shortening of 1 to 2 cm is an expected trade-off that must be discussed before surgery.

Plaque incision or excision with grafting: The plaque is incised or partially removed and covered with a graft (collagen matrix, pericardium, or vein). Preserves more length than plication but carries higher risk of post-operative erectile dysfunction (5%, 25% depending on technique and baseline function) [3].

Inflatable penile prosthesis (IPP) with intraoperative modeling: The preferred approach when significant vascular erectile dysfunction coexists with Peyronie's disease. Satisfaction rates for IPP in this population range from 80% to 96% in series reported by the Society for the Study of Male Reproduction [12]. Intraoperative manual modeling or adjunctive incision and grafting at the time of prosthesis placement corrects residual curvature.

The HealthRX clinical team uses the following decision pathway to stratify Peyronie's patients toward the right treatment tier:

1. Acute phase, pain dominant, curvature <30 degrees: PTT plus PDE5i for pain and erectile function support; monitor at 3-month intervals.
2. Acute or early stable, curvature 30, 90 degrees, no calcification, preserved erectile function: CCH injection series (up to 4 cycles) combined with PTT modeling.
3. Stable phase, curvature >30 degrees, CCH failed or calcified plaque: Surgical consultation; plication if length is adequate and EF is preserved; grafting if complex geometry.
4. Any phase, severe vascular ED (IIEF-5 <12) plus curvature: Direct referral to prosthetic urology for IPP with intraoperative modeling.

Peyronie's Disease and Erectile Dysfunction

The overlap between Peyronie's disease and erectile dysfunction (ED) is substantial. A systematic review published in Sexual Medicine Reviews found that 58% of men with Peyronie's disease reported concurrent ED [13]. The mechanisms are multiple and often additive.

Mechanically, the rigid plaque obstructs venous occlusion during erection, causing venous leak-pattern ED detectable on duplex Doppler as elevated end-diastolic velocity. Psychologically, anticipatory pain and anxiety about appearance substantially reduce arousal. The shared vascular risk factors of hypertension, diabetes, and dyslipidemia contribute independently to both conditions.

Treating ED in the Peyronie's patient requires addressing both components. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) remain first-line for vascular ED and can be prescribed alongside CCH treatment. Intracavernosal injection of alprostadil (10 to 20 mcg) is effective when oral PDE5i fails. Men with baseline IIEF-5 scores below 12 are unlikely to achieve functional erections after plication or grafting alone and should be counseled about IPP from the outset.

As the AUA Peyronie's Disease Guideline states: "Clinicians should counsel patients with Peyronie's disease who have concurrent erectile dysfunction that treatment of erectile dysfunction alone may not adequately address their penile deformity or associated bother." [3]

How Peyronie's Disease Affects Libido and Ejaculation

The psychological burden of Peyronie's disease suppresses libido in a meaningful proportion of men. A cross-sectional study of 245 men with Peyronie's disease found that 48% reported reduced sexual desire compared to pre-disease baseline, with PDQ emotional bother scores correlating more strongly with libido decline than curvature degree alone [14].

Low libido (hypoactive sexual desire) in Peyronie's patients warrants evaluation beyond the mechanical disorder. Testosterone deficiency is an independent co-morbidity: men with Peyronie's disease have higher rates of hypogonadism than age-matched controls, possibly because the inflammatory cytokines involved in plaque formation also suppress the hypothalamic-pituitary-gonadal axis [15]. A morning total testosterone level should be obtained in any Peyronie's patient reporting low libido or fatigue. The Endocrine Society defines biochemical hypogonadism as a total testosterone level consistently below 300 ng/dL in the context of signs and symptoms [16].

Ejaculatory dysfunction, both premature ejaculation (PE) and delayed ejaculation (DE), co-occurs with Peyronie's disease more frequently than in the general male population. Pain during erection and performance anxiety alter arousal thresholds, which may accelerate or blunt the ejaculatory reflex depending on the individual. Selective serotonin reuptake inhibitor (SSRI) dapoxetine (60 mg on-demand) is the only agent specifically approved for PE in countries outside the United States and has strong randomized trial support [17]. For DE, behavioral techniques addressing anxiety and pelvic floor tension are first-line before pharmacological intervention.

Peyronie's Disease After Prostate Cancer Treatment

Radical prostatectomy increases Peyronie's disease risk. A 2014 prospective study of 388 post-prostatectomy men found new penile curvature in 15.9% at 12 months post-surgery, compared to background population rates under 2% in the same age group [6]. The mechanism is traction neuropraxia and vascular ischemia during penile flaccidity post-surgery, which triggers the same TGF-beta 1 fibrotic cascade as trauma.

Penile rehabilitation protocols (daily PDE5i, vacuum erection devices starting within weeks of surgery) may reduce post-prostatectomy curvature incidence by preserving oxygenation of tunica albuginea tissue. The evidence base is mixed but biologically plausible. Men undergoing radical prostatectomy should be told their Peyronie's risk before surgery and counseled to report any new curvature or palpable nodule promptly.

Psychological Impact and Partner Considerations

Peyronie's disease carries a psychological burden comparable to other chronic urological conditions. A 2019 study in BJU International measuring Patient Health Questionnaire-9 (PHQ-9) scores found clinically significant depressive symptoms in 39% of men presenting with Peyronie's disease, with scores inversely correlated with IIEF-5 scores and directly correlated with PDQ bother [18].

Partners are affected too. Dyspareunia for the partner, reduced frequency of intercourse, and relationship distress are reported in controlled partner interviews. Incorporating a partner into the clinical visit, when the patient consents, improves treatment adherence and couples' coping. Several sexual medicine guidelines recommend brief psychological consultation as part of multi-modal Peyronie's care, particularly when anxiety or depression is identified [3].

Dr. Laurence Levine, Professor of Urology at Rush University Medical Center and a lead author on the AUA Peyronie's Disease Guideline, has noted: "The psychological impact of Peyronie's disease is often as debilitating as the physical deformity, and addressing both components is essential to achieving satisfactory outcomes." [3]

When to See a Specialist

Any man who notices a new penile nodule, painful erection, or change in penile shape should seek evaluation within 4 to 6 weeks rather than waiting for symptoms to plateau. Early intervention during the acute phase, when plaque collagen is still being deposited, offers the best window for non-surgical treatment to modify the trajectory of the disease.

Referral to a urologist with fellowship training in sexual medicine or reconstructive urology is appropriate for:

• Curvature >30 degrees
• Hourglass or hinge deformity affecting rigidity
• Penile shortening of 1 cm or more
• Coexistent ED unresponsive to oral PDE5 inhibitors
• Any degree of deformity causing psychological distress or relationship difficulty

A baseline IIEF-5 score below 17 at first presentation predicts a 3.2-fold higher likelihood of requiring IPP rather than plication at 24-month follow-up, making early stratification valuable for setting realistic expectations [13].